As a result, the demand for effective long-term glycemic control has led to the widespread use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have become a cornerstone in the management of T2DM [19–21]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.